A postdoctoral position is available at Oligomerix, Inc, New York. The research will enable the small molecule tau aggregation inhibitor program. It will include developing and characterizing novel antibodies suitable for use as biomarkers for tau, development and characterization of cell models of tau aggregation, and assessment of efficacy in mouse models of tauopathy
Oligomerix, Inc. offers a stimulating research environment with established researchers interested in developing novel therapeutics for AD and related tauopathies, and supported by state-of-the-art research facilities.
Candidates must hold a Ph.D. in Neuroscience, Cell Biology or a relevant field, and have a strong background in cell and animal models of AD or tauopathy. The ideal candidate will have expertise in screening and testing antibodies using human CSF, plasma and brain tissue. Experience in tissue culture, protein biochemistry and in vivo studies of tau protein are also highly desirable.
Applications will be accepted on a rolling basis and candidates will be considered until the position is filled. To be considered, all applicants must submit in PDF format: a cover letter summarizing research experience and specifying the interests in this position; a curriculum vitae (including a full list of publications); a statement of research interests; and the names and contact details for three references. For questions related to this position, please email email@example.com.
Additional Salary Information: Prospective candidates will be asked to provide a salary history.
Oligomerix® is a highly differentiated biopharmaceutical company discovering and developing novel therapeutics for Alzheimer’s disease (AD) and related neurodegenerative diseases such as chronic traumatic encephalopathy (CTE) caused by head injury. Founded in 2006, the Company has a small molecule inhibitor program and an associated biomarker that target tau oligomers, the small aggregates of tau ...protein that are implicated in the spread of pathology and the impairment of memory formation in neurodegenerative disease. Tau protein (monomer) maintains the structure of neurons necessary for the transmission of signals between neurons. During AD, tau loses its normal function when it forms oligomers. Small molecules inhibitors are being developed to block tau self-association into oligomers, thereby preventing both tau loss of function and gain of toxic function. Antibody biomarkers are being developed to support these approaches that also have potential as immunotherapeutics.